4_5949770516716855578.pdf
2.8 MB
Estimates of global and regional prevalence of Helicobacter pylori
infection among individuals with obesity: a systematic review
and meta‑analysis
infection among individuals with obesity: a systematic review
and meta‑analysis
gong-feng-non-invasive-tests-of-fibrosis-in-the.pdf
1.6 MB
Non- invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring.
BMJ 2025
BMJ 2025
john-gásdal-karstensen-performance-measures-for.pdf
752 KB
Performance measures for endoscopic ultrasound: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative– Update 2025
❤1
Canadian-Adult-Obesity-CPG-Pharmacotherapy-2025-update.pdf
674.3 KB
Canadian Adult Obesity Clinical Practice Guideline: Pharmacotherapy for Obesity 2025 clinical practice guideline update
✳️ NSAIDs use in IBD patients
▶️ Current ACG guidelines recommend viewing routine NSAID use with caution in Crohn's disease patients, noting they may exacerbate disease activity.
▶️ British Society of Gastroenterology guidelines (BSG) indicate short-term use is relatively safe when IBD is well-controlled, with approximately 20% relapse risk, and that selective COX-2 inhibitors show no difference from placebo in meta-analyses.
▶️ NSAIDs should be avoided in acute severe ulcerative colitis, as they have been associated with IBD-related hospitalizations and disease relapses.
▶️ When pain management is needed, consider acetaminophen as an alternative, though one study found it was also associated with active Crohn's disease (possibly as a marker of subclinical disease activity rather than causation).
▶️ If NSAIDs are necessary, consider selective COX-2 inhibitors or low-dose aspirin as potentially safer alternatives for short-term use in patients with well-controlled disease.
▶️ Current ACG guidelines recommend viewing routine NSAID use with caution in Crohn's disease patients, noting they may exacerbate disease activity.
▶️ British Society of Gastroenterology guidelines (BSG) indicate short-term use is relatively safe when IBD is well-controlled, with approximately 20% relapse risk, and that selective COX-2 inhibitors show no difference from placebo in meta-analyses.
▶️ NSAIDs should be avoided in acute severe ulcerative colitis, as they have been associated with IBD-related hospitalizations and disease relapses.
▶️ When pain management is needed, consider acetaminophen as an alternative, though one study found it was also associated with active Crohn's disease (possibly as a marker of subclinical disease activity rather than causation).
▶️ If NSAIDs are necessary, consider selective COX-2 inhibitors or low-dose aspirin as potentially safer alternatives for short-term use in patients with well-controlled disease.
❤3
ACG_clinical_guideline_update__preventive_care_in.15.pdf
661.7 KB
ACG Guideline Clinical Update : Preventive Care in Inflammatory Bowel Disease
July 2025
Functional dyspepsia 2026.pdf
3.9 MB
Functional dyspepsia
NEJM jan.2026
Appendectomy in UC remission versus JAk inhibitors .pdf
5.6 MB
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of
a multicentre, prospective, cohort study
✴️ Conclusion : Appendicectomy as an adjunct to advanced therapy in biologic-exposed patients with active ulcerative colitis was associated with higher clinical remission rates at 12 months compared with switching to a JAK inhibitor, suggesting potential effectiveness, and the procedure can be performed safely in this patient group.
a multicentre, prospective, cohort study
✴️ Conclusion : Appendicectomy as an adjunct to advanced therapy in biologic-exposed patients with active ulcerative colitis was associated with higher clinical remission rates at 12 months compared with switching to a JAK inhibitor, suggesting potential effectiveness, and the procedure can be performed safely in this patient group.
The lancet gastro&Hep 2025
🔥2❤1